DogStem

Development

Clinical development

The results of the clinical trial are based on the study of the lameness in a plate-force platform as primary endpoint. This test allows us to evaluate the evolution of lameness objectively, comparing the weight that the animal carries on each limb and thus being able to assign a numerical value to the degree of lameness.

The use of tools that make it possible to transform a typically subjective measure such as pain and lameness into a quantitative variable by force platform gives robustness to the results that have been rare until now.

DogStem does not seek only a partial improvement, but a substantial improvement in the quality of life and reduction of pain

Lameness reduction

Preliminary results show that 63% of the dogs treated with DogStem improved their gait analysis on the plate-force, demonstrating a lower degree of lameness and joint pain, whereas no dog treated with placebo improved their gait analysis.

%

SUCCESS OF THE TREATMENT GROUP

%

SUCCESS OF THE PLACEBO GROUP

Orthopedic Assessment

collaborating hospitals carry out an orthopedic evaluation at different times after the infiltration.

In the orthopedic examination performed, 77% of the patients treated with stem cells showed improvement in the infiltrated joint, compared to a placebo effect of 46%.

%

SUCCESS OF THE TREATMENT GROUP

%

SUCCESS OF THE PLACEBO GROUP

Improvement of quality of life

According owners opinion, 65% of dogs treated with DogStem substantially improved their quality of life after treatment, while only 19% of dogs treated with placebo saw improvement.

The improvement of the quality of life was evaluated by the owners in activities of daily life of our pets such as walking, playing with other dogs, getting on the sofa, climbing stairs, etc.

%

SUCCESS OF THE TREATMENT GROUP

%

SUCCESS OF THE PLACEBO GROUP

Clinical results

Preclinical

Preclinical 100%

Collection of safety and efficacy data in the intra-articular use of autologous mesenchymal stem cells in dogs with Osteoarthritis

Phase I

Safety 100%

Single and repeated dose

*VICH GL9

Immunogenicity clinical trial: Cellular and Humoral response

*VICH GL9

Phase II

Exploratory 100%

Exploratory study of safety and efficacy in canine osteoarthritis (OA) treated with mesenchymal stem cells versus placebo in pilot animals

*VICH GL9

Phase III

Confirmatory 100%

Confirmatory clinical trial of safety and efficacy in the use of DogStem in dogs with mild to severe osteoarthritis (OA) under field conditions

*VICH GL9